Revolution Medicines wins FDA approval for $39,800 pancreatic cancer drug
The FDA has approved Revolution Medicines’ Rasonque for metastatic pancreatic cancer, validating a once-thought-undruggable protein target that could unlock a broader oncology platform and reshape cancer treatment economics.
The Food and Drug Administration approved Rasonque on Wednesday for adults with metastatic pancreatic adenocarcinoma who have exhausted one prior treatment or cannot tolerate combination chemotherapy. The once-daily pill, developed by Revolution Medicines, targets the RAS protein mutation without requiring a prior genetic test to identify specific variations.
The approval validates a mechanism long deemed impossible to target directly, offering a potential blueprint for treating roughly a quarter of all human cancers. Revolution Medicines set a list price of $39,800 for a 30-day supply, though a new support program allows eligible insured patients to pay nothing out of pocket.
For investors, the regulatory green light represents more than a single commercial asset. Early shareholder Dr. Danish Nagda views the approval as proof of a broader therapeutic platform capable of attacking the molecular core of multiple tumor types.
“Instead of developing one drug for just pancreatic cancer, they’ve actually built an entire platform to go after this core issue called RAS,” Nagda said. Because the drug succeeds in one of oncology’s most resistant diseases, he expects off-label utilization across other cancer types to expand rapidly.
In the pivotal trial, patients with previously treated metastatic disease lived a median of 13.2 months on Rasonque, compared to 6.7 months on standard chemotherapy. The therapy reduced the risk of death by 60% and extended the time before disease progression and quality-of-life decline.
The FDA granted the application Breakthrough Therapy and Orphan Drug designations, reviewing it under the National Priority Voucher pilot program. The decision arrived 6.5 months ahead of the user-fee deadline, aided by new agency rules allowing international regulators to assist in oncology reviews.
Pancreatic adenocarcinoma accounts for up to 95% of pancreatic cases and remains highly lethal. An estimated 67,530 Americans will receive a diagnosis in 2026, with about 52,740 expected to die, according to the American Cancer Society.
The five-year survival rate for the disease remains stuck at 13%, the lowest among major cancers. Brian Wolpin, the trial’s principal investigator at Dana-Farber Cancer Institute, noted the approval “gives physicians the confidence that directly inhibiting RAS can make a striking difference for patients.”
Revolution Medicines is already advancing a related compound, daraxonrasib, through late-stage lung cancer trials. An expanded access program for Rasonque launched in May and has already treated more than 2,000 patients.
Looking ahead, Nagda contrasted this intracellular approach with surface-level mRNA cancer vaccines, suggesting the two methods could eventually combine. “I think we are within five years of us having combination therapies that essentially get rid of the cancer,” he said.
